Invigo is representing Bayer AG in its participation as project leader to the Innovative Medicines Initiative 2 consortium project named “ESCulab”, the main purpose of which is to set-up a European screening centre for compound high-throughput and high content screening on targets of interest.

The consortium consists of a conglomerate of pharmaceutical companies, SMEs, and academic institutions.

Invigo was involved in the negotiations on the consortium agreement, and will also be providing legal advice during the project.